CellCentric, a Cambridge, UK-based clinical-stage biotechnology firm, raised $120M in Collection C funding.
The spherical was led by RA Capital Administration and new investor Forbion, with participation from Avego Bioscience Capital, in addition to BrightEdge, the American Most cancers Society’s enterprise capital and affect funding arm.
Led by CEO Will West, CellCentric is a scientific stage biotech firm advancing Inobrodib, which is a brand new therapy for folks with most cancers, and a number of myeloma specifically. Its small molecule drug targets p300/CBP, decreasing the expression of key most cancers drivers, MYC and IRF4. Delivered as an oral capsule, it may be used at residence with out the necessity for intensive monitoring. Because it has a very good security profile for a drug on this setting, it could be utilized by those that are unable to entry or tolerate different sorts of therapy.
The corporate intends to make use of the funds to:
- Speed up the Part II/III examine in closely pretreated a number of myeloma sufferers, with the potential to help an accelerated approval.
- Help improvement actions for a Part III program, to begin mid-2026.
- Speed up trials beginning Q2 2025, together with the mix of inobrodib with bi-specific antibodies, in addition to inobrodib in a upkeep setting.
FinSMEs
19/05/2025
